European committee takes a second look at Alzheimer's drug and …
22 hours ago · A European regulatory committee now recommends approval of the Alzheimer’s treatment lecanemab a few months after rejecting the drug.. Biogen said Thursday that the drug, known in the U.S. as Leqembi, received a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for Human Use as a treatment for early Alzheimer’s disease.
Biogen to Realign Resources for Alzheimer's Disease Franchise
CAMBRIDGE, Mass., Jan. 31, 2024 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced plans to reprioritize its resources in Alzheimer’s disease (AD), a strategic therapeutic area expected to drive near and long-term growth.
Biogen’s Decision to Discontinue Alzheimer’s Drug | alz.org
CHICAGO, Jan. 31, 2024 — Despite today’s announcement from Biogen, the Alzheimer’s Association is extremely optimistic about the future of Alzheimer’s treatments; a new era that started with the Food and Drug Administration (FDA) accelerated approval of Aduhelm in 2021.
Biogen discontinues Alzheimer’s medication Aduhelm - CNN
Jan 31, 2024 · The Alzheimer’s medication Aduhelm is being discontinued by drugmaker Biogen as it shifts resources to its other Alzheimer’s medication, Leqembi, and developing other treatments, the company...
Ticker: Biogen Alzheimer's drug gets second look in EU; Ford …
20 hours ago · A European regulatory committee now recommends approval of the Alzheimer’s treatment lecanemab a few months after rejecting the drug. Biogen said Thursday that the drug, known in the U.S. as ...
Biogen to shut down controversial Alzheimer's drug Aduhelm | AP News
Jan 31, 2024 · Biogen will stop selling its Alzheimer’s treatment Aduhelm, a drug once seen as a potential blockbuster that stumbled after its launch a few years ago. The drugmaker also said Wednesday that it will end a study of the drug needed for …
Biogen Abandons Its Controversial Alzheimer’s Drug Aduhelm
Jan 31, 2024 · The drug maker Biogen said on Wednesday it would abandon its ownership rights to Aduhelm, an Alzheimer’s drug that had provoked fierce criticism of the company and regulators after it was...
Biogen to stop selling controversial Alzheimer's drug Aduhelm - NBC News
Jan 31, 2024 · Biogen will stop developing its Alzheimer’s treatment Aduhelm, a drug once seen as a potential blockbuster before stumbling soon after its launch a couple years ago.
Biogen to cease production of controversial Alzheimer’s drug
Jan 31, 2024 · Drugmaker Biogen will discontinue development and marketing for Aduhelm, a landmark Alzheimer’s disease treatment that also provoked controversy over conflicting data around its efficacy, the...
Biogen Is Dropping Controversial Alzheimer's Drug Aduhelm - U.S. News …
WEDNESDAY, Jan. 31, 2024 (HealthDay News) -- Biogen, maker of the Alzheimer's medicine Aduhelm, announced Wednesday that it would "discontinue the development and commercialization" of the...